Breaking News Instant updates and real-time market news.

ZGNX

Zogenix

$55.85

9.5 (20.50%)

08:00
07/13/18
07/13
08:00
07/13/18
08:00

Zogenix price target raised to $92 from $52 at Leerink

Leerink analyst Geoffrey Porges raised his price target for Zogenix to $92 from $52 after the company reports topline data from its second Dravet phase 3 study yesterday, stating that the data appear to represent a "best case scenario" given they approximate study one's strong efficacy and show clean cardiac safety. Porges, who thinks yesterday's 21% advance in the shares was a "reasonable reflection of the confirmation of the drug's profile," maintains an Outperform rating on Zogenix shares.

ZGNX Zogenix
$55.85

9.5 (20.50%)

07/12/18
MZHO
07/12/18
NO CHANGE
Target $69
MZHO
Buy
Zogenix price target raised to $69 from $51 at Mizuho
Mizuho analyst Difei Yang raised her view on the probability of success for ZX008 in Dravet syndrome to 100% after the company reported positive results from its second phase 3 study of the drug. Yang, who called the study "the last roadblock" prior to submitting regulatory applications in the U.S. and Europe for ZX008 in Dravet, increased her price target on Zogenix to $69 and keeps a Buy rating on the shares.
04/20/18
MZHO
04/20/18
NO CHANGE
Target $51
MZHO
Buy
Mizuho reiterates Buy on Zogenix after GW Pharmaceuticals FDA panel
After an FDA panel unanimously voted in favor of approving GW Pharmaceuticals' (GWPH) Epidiolex, Mizuho analyst Difei Yang reiterates a Buy rating on Zogenix (ZGNX) with a $51 price target. Superior efficacy of Zogenix competitor ZX008, as demonstrated in the most recent Phase 3 results, means that FDA approval would be highly likely assuming positive data from the second Phase 3 study, expected in June, Yang tells investors in a research note. She believes readouts on the study could be an important share moving event and are "highly likely" to be positive.
02/23/18
LEER
02/23/18
NO CHANGE
Target $54
LEER
Outperform
Leerink optimistic on Zogenix extending exclusivity period of ZX008
Leerink analyst Paul Matteis raised his price target for Zogenix to $54 from $54 and reiterates an Outperform rating on the shares in a research note titled "Are Investors Sleeping on ZGNX's Path to ZX008 IP Protection?" The analyst's research makes him optimistic regarding the path for Zogenix to extend the exclusivity period of ZX008 in Dravet syndrome beyond the consensus expectation of seven-and-a-half years of orphan/pediatric drug exclusivities. He sees a "reasonable chance" that potential ZX008 generic drug manufacturers could be delayed as a result of recently issued method of treatment patents. Matteis expects this extension story will continue to develop during the course of 2018.
11/27/17
JMPS
11/27/17
INITIATION
Target $56
JMPS
Outperform
Zogenix initiated with an Outperform at JMP Securities
JMP Securities analyst Jason Butler started Zogenix with an Outperform rating and $56 price target, saying he thinks the potential for ZX008 in seizure disorders beyond Dravet syndrome is currently underappreciated.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$292.44

31.41 (12.03%)

14:44
10/23/18
10/23
14:44
10/23/18
14:44
Hot Stocks
Musk says Tesla will cut some interior configuration options for Model S, X »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 13

    Dec

VNQ

Vanguard REIT Index Fund

$77.68

0.64 (0.83%)

14:40
10/23/18
10/23
14:40
10/23/18
14:40
Options
66K Vanguard Real Estate Fund Dec 76 - Jan 72 put spreads trade 71c »

66K Vanguard Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEEV

Veeva

$88.99

-2.77 (-3.02%)

14:35
10/23/18
10/23
14:35
10/23/18
14:35
Options
Veeva put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
10/23/18
10/23
14:35
10/23/18
14:35
General news
Fed Board minutes showed showed most Banks supported the September 26 rate hike »

Fed Board minutes showed…

TSLA

Tesla

$292.00

30.97 (11.86%)

14:32
10/23/18
10/23
14:32
10/23/18
14:32
Recommendations
Tesla analyst commentary  »

Tesla's moved up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 13

    Dec

TTWO

Take-Two

$118.82

-1.69 (-1.40%)

14:30
10/23/18
10/23
14:30
10/23/18
14:30
Periodicals
'Red Dead Redemption 2' development a difficult experience, Kotaku says »

Take-Two's Rockstar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

SELB

Selecta Biosciences

$9.25

-4.12 (-30.82%)

, HZNP

Horizon Pharma

$18.49

-0.76 (-3.95%)

14:29
10/23/18
10/23
14:29
10/23/18
14:29
Recommendations
Selecta Biosciences, Horizon Pharma analyst commentary  »

Selecta SEL-212 data…

SELB

Selecta Biosciences

$9.25

-4.12 (-30.82%)

HZNP

Horizon Pharma

$18.49

-0.76 (-3.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 27

    Nov

BCS

Barclays

$8.60

0.11 (1.30%)

14:20
10/23/18
10/23
14:20
10/23/18
14:20
Options
8-strike put buyers in Barclays Bank ahead of earnings »

8-strike put buyers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SELB

Selecta Biosciences

$8.93

-4.44 (-33.21%)

14:19
10/23/18
10/23
14:19
10/23/18
14:19
Recommendations
Selecta Biosciences analyst commentary  »

Selecta Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SLG

SL Green Realty

$92.15

0.36 (0.39%)

14:18
10/23/18
10/23
14:18
10/23/18
14:18
Downgrade
SL Green Realty rating change  »

SL Green Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/23/18
10/23
14:17
10/23/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$133.39

-7.945 (-5.62%)

14:16
10/23/18
10/23
14:16
10/23/18
14:16
Recommendations
Centene analyst commentary  »

Centene should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 14

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/23/18
10/23
14:16
10/23/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$22.65

-1.255 (-5.25%)

14:15
10/23/18
10/23
14:15
10/23/18
14:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

SBH

Sally Beauty

$17.78

0.28 (1.60%)

14:09
10/23/18
10/23
14:09
10/23/18
14:09
Hot Stocks
Sally Beauty unveils Sally Beauty Rewards »

"Sally Beauty …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICAD

iCAD

$3.10

-0.02 (-0.64%)

14:06
10/23/18
10/23
14:06
10/23/18
14:06
Hot Stocks
iCAD announces new clinical data on the Xoft Electronic Brachytherapy System »

iCAD announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

AMD

AMD

$24.73

-0.31 (-1.24%)

14:05
10/23/18
10/23
14:05
10/23/18
14:05
Hot Stocks
AMD, Oracle collaborate on EPYC processor-based offering »

At Oracle's (ORCL)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Dec

UNH

UnitedHealth

$261.89

-0.26 (-0.10%)

14:05
10/23/18
10/23
14:05
10/23/18
14:05
Options
UnitedHealth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$152.62

-2.19 (-1.41%)

14:03
10/23/18
10/23
14:03
10/23/18
14:03
Hot Stocks
Facebook introduces Messenger 4 »

In a blog posting,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

14:00
10/23/18
10/23
14:00
10/23/18
14:00
General news
Breaking General news story  »

Dallas Federal Reserve…

KR

Kroger

$28.16

0.17 (0.61%)

13:58
10/23/18
10/23
13:58
10/23/18
13:58
Hot Stocks
Kroger hiring 10,000 associates for holiday season »

The Kroger Co. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

EXAS

Exact Sciences

$63.00

0.68 (1.09%)

13:55
10/23/18
10/23
13:55
10/23/18
13:55
Periodicals
Exact Sciences named a core healthcare short at Hedgeye »

Hedgeye named Exact…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

EOG

EOG Resources

$110.23

-6.03 (-5.19%)

13:55
10/23/18
10/23
13:55
10/23/18
13:55
Options
EOG Resources put volume heavy and directionally bearish »

Bearish flow noted in EOG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

SELB

Selecta Biosciences

$9.06

-4.31 (-32.24%)

, HZNP

Horizon Pharma

$18.52

-0.735 (-3.82%)

13:53
10/23/18
10/23
13:53
10/23/18
13:53
Hot Stocks
Street Fight: Analysts diverge on Selecta Bio's gout drug data read-through »

Shares of Selecta…

SELB

Selecta Biosciences

$9.06

-4.31 (-32.24%)

HZNP

Horizon Pharma

$18.52

-0.735 (-3.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 27

    Nov

13:50
10/23/18
10/23
13:50
10/23/18
13:50
General news
Fed's Bostic continues to tout a gradual path of tightening »

Fed's Bostic…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.